Get the Stockscreener App
1.40
0.00%
0.00
Biocardia Inc stock is traded at $1.40, with a volume of 33,293.
It is up +0.00% in the last 24 hours and up +2.94% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$1.40
Open:
$1.42
24h Volume:
33,293
Relative Volume:
0.05
Market Cap:
$8.13M
Revenue:
$3,000
Net Income/Loss:
$-8.79M
P/E Ratio:
-0.6656
EPS:
-2.1033
Net Cash Flow:
$-8.46M
1W Performance:
+6.87%
1M Performance:
+2.94%
6M Performance:
-47.76%
1Y Performance:
-41.42%
1-Day Range:
$1.35
$1.42
1-Week Range:
$1.25
$1.43
52-Week Range:
$1.00
$3.20
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
3.32 | 4.40B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.06 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.3926 | 189.47M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.255 | 554.19M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.38 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
Price action breakdown for BioCardia Inc.July 2025 Snapshot & High Accuracy Trade Alerts - newser.com
How to forecast BioCardia Inc. trends using time seriesQuarterly Profit Review & Reliable Price Action Trade Plans - newser.com
Is BioCardia Inc. forming a bottoming baseMarket Performance Recap & Reliable Price Breakout Alerts - newser.com
Why BioCardia Inc. stock could benefit from AI revolution2025 EndofYear Setup & Free Expert Verified Stock Movement Alerts - newser.com
Can BioCardia Inc. stock sustain institutional interestJuly 2025 Decliners & Weekly Breakout Watchlists - newser.com
How BioCardia Inc. (6JU0) stock responds to job market shiftsWeekly Stock Recap & High Return Stock Watch Alerts - newser.com
What to expect from BioCardia Inc. in the next 30 daysTrade Performance Summary & Long-Term Capital Growth Strategies - newser.com
BioCardia’s CardiAMP HF II Phase 3 Trial Reaches Milestone With First Patient Enrollment At University Of Wisconsin - Pulse 2.0
Will BioCardia Inc. (6JU0) stock return to pre crash levelsQuarterly Market Review & Real-Time Stock Price Movement Reports - newser.com
Can BioCardia Inc. stock hit record highs againJuly 2025 Gainers & Technical Pattern Based Buy Signals - newser.com
Applying sector rotation models to BioCardia Inc.Quarterly Portfolio Review & Fast Exit and Entry Trade Guides - newser.com
Smart tools for monitoring BioCardia Inc.’s price actionQuarterly Trade Report & Safe Entry Momentum Tips - newser.com
Is BioCardia Inc. stock positioned for digital transformationGap Up & Real-Time Buy Signal Alerts - newser.com
Measuring BioCardia Inc.’s beta against major indicesMarket Activity Recap & Daily Technical Forecast Reports - newser.com
What is the fair value estimate for BioCardia Inc. (6JU0) stock in 2025Day Trade & Real-Time Price Movement Reports - newser.com
What catalysts could drive BioCardia Inc. stock higherAnalyst Downgrade & Safe Entry Zone Identification - newser.com
Published on: 2025-10-31 00:08:58 - newser.com
Why BioCardia Inc. (6JU0) stock appears on watchlistsNew Guidance & Free Real-Time Volume Trigger Notifications - newser.com
Custom watchlist performance reports with BioCardia Inc.Risk Management & Consistent Income Trade Recommendations - newser.com
BioCardia, Inc. (BCDA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
BioCardia enrolls first patient at UW in phase 3 heart failure trial - Investing.com Philippines
BioCardia Advances Phase 3 CardiAMP HF II Trial - TipRanks
BioCardia, Inc. Enrolls First Patient in Phase 3 CardiAMP HF II Trial - TradingView
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial - The Manila Times
BCDA reports first patient enrollment in Phase 3 CardiAMP HF II - Stock Titan
BioCardia (NASDAQ: BCDA) reports first UW patient enrolled in Phase 3 CardiAMP HF II - Stock Titan
BCDA amends Q2 filing; going concern flagged, $769k ATM raised - Stock Titan
Using flow based indicators on BioCardia Inc.Weekly Loss Report & Long-Term Capital Growth Strategies - newser.com
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocardia Inc Stock (BCDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Blank Andrew Scott | Director |
Sep 19 '25 |
Buy |
1.25 |
288,000 |
360,000 |
634,023 |
| Altman Peter | President and CEO |
Sep 19 '25 |
Buy |
1.25 |
48,000 |
60,000 |
216,762 |
| Altman Peter | President and CEO |
Aug 22 '25 |
Buy |
1.83 |
700 |
1,281 |
168,762 |
| Altman Peter | President and CEO |
Aug 13 '25 |
Buy |
1.83 |
100 |
183 |
168,062 |
| Altman Peter | President and CEO |
Aug 12 '25 |
Buy |
1.75 |
400 |
700 |
167,962 |
| Altman Peter | President and CEO |
Aug 11 '25 |
Buy |
1.76 |
1,700 |
2,989 |
167,562 |
| McClung David | Chief Financial Officer |
Jun 30 '25 |
Buy |
2.08 |
4,819 |
9,999 |
47,950 |
| Altman Peter | President and CEO |
Jun 30 '25 |
Buy |
2.08 |
24,096 |
49,999 |
165,862 |
| STERTZER SIMON H | Director |
Jun 30 '25 |
Buy |
2.08 |
72,289 |
150,000 |
192,654 |
| Blank Andrew Scott | Director |
Jun 30 '25 |
Buy |
2.08 |
72,289 |
150,000 |
346,023 |
0.03%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):